100 mg/mL; 30 mL vial
(NDC 0409-3307-03)
200 mg/mL; 30 mL vial
(NDC 0409-3308-03)

Product 100 mg/mL; 30 mL vial (NDC 0409-3307-03):  next delivery April.

Product 200 mg/mL; 30 mL vial (NDC 0409-3308-03):  next delivery April.

Please check with your wholesaler for available inventory.

Reverified

3/2/2012

200 mg/mL, 10 mL (NDC 00054-3028-02), 200 mg/mL, 30 mL (NDC 00054-3026-02)

Roxane Laboratories has all acetylcysteine inhalation solution presentations on backorder and the company cannot provide an anticipate release date.

100 mg/mL, 4 mL (NDC 00517-7504-25), 100 mg/mL, 10 mL (NDC 00517-7510-03), 200 mg/mL, 4 mL (NDC 00517-7604-25), 200 mg/mL, 10 mL (NDC 00517-7610-03), 200 mg/mL, 30 mL (NDC 00517-7630-03)

0.5 mg/ml; 2ml ampule (NDC 17478-0067-02)

0.5 mg/ml; 5ml ampule (NDC 17478-0067-05)

2 mL (NDC 17478-0067-02) due to release in April.

5 mL (NDC 17478-0067-05) due to release in April.

500 mcg/mL; 2 mL amp (NDC 0409-2266-02)

500 mcg/mL; 5 mL amp (NDC 0409-2266-05)

Product 500 mcg/mL, 2 mL amp (NDC 0409-2266-02): next delivery May.

Product 500 mcg/mL; 5 mL amp (NDC 0409-2266-05): next delivery May.

Please check your wholesaler for all available inventory.

Teva Pharmaceuticals
1-800-545-8800

250 mg/mL, 2 mL vials (NDC 55390-0226-02)
250 mg/mL, 4 mL vials (NDC 55390-0226-04)

Aminosyn II 10%, Sulfite-free; 1 L bag (NDC 0409-4164-05)

Aminosyn 10%, Sulfite-free; 500 mL bag (NDC 0409-4191-03)

Aminosyn 8.5%, Sulfite-free; 500 mL bag (NDC 0409-4187-03)

Aminosyn II 10%; 2 L bag (NDC 0409-7121-07)

Aminosyn II 15%, Sulfite-free; 2 L bag (NDC 0409-7171-17)

Aminosyn 10%, Sulfite-free, 1 L (NDC 0409-4191-05)

Aminosyn II 10%, 500 mL, Sulfite-free (NDC 0409-4164-03)

Aminosyn HBC 7%, 500 mL, Sulfite-free (NDC 0409-4168-03)

Aminosyn 3.5%, sulfite-free, 1 L (NDC 0409-4196-05)

Aminosyn 8.5%, sulfite-free, 500 mL (NDC 0409-4187-03)

Aminosyn 10%, sulfite-free, 500 mL (NDC 0409-4191-03)

Aminosyn II 8.5%, sulfite-free, 500 mL (NDC 0409-4162-03)

Aminosyn II 8.5% with electrolytes, sulfite-free, 500 mL (NDC 0409-4171-03)

Aminosyn II 10%, sulfite-free, 1L (NDC 0409-4164-05)

Aminosyn-PF 7%, sulfite-free, 500 mL (NDC 0409-4178-03)

Aminosyn-PF 10%, 1000 mL, sulfite-free (NDC 0409-4179-05)

Aminosyn RF 5.2%, 500 mL, sulfite-free (NDC 0409-4166-03)

Product Aminosyn 10%, Sulfite-free; 500 mL bag (NDC 0409-4191-03): ample supply available.

Product Aminosyn 8.5%, Sulfite-free; 500 mL bag (NDC 0409-4187-03): next delivery March.

Product Aminosyn 8.5%, Sulfite-free with Electrolytes, 500 mL (NDC 0409-4203-03): ample supply available.

Product Aminosyn II 10%; 2 L bag (NDC 0409-7121-07): next delivery July.

Product Aminosyn II 15%, Sulfite-free; 2 L bag (NDC 0409-7171-17): next delivery July.

Product Aminosyn 10%, Sulfite-free, 1L (NDC 0409-4191-05): ample supply available.

Product Aminosyn II 10%, 500 mL, Sulfite-free (NDC 0409-4164-03): ample supply available.

Product Aminosyn HBC 7%, 500 mL, Sulfite-free (NDC 0409-4168-03): next delivery TBD.

Please check with your wholesaler for available inventory.

Other presentations available.

Please see the Dear Customer Letter (PDF - 31KB)

TrophAmine 6%, 500 mL (NDC 00264-9361-55)

TrophAmine 10%, 500 mL (NDC 00264-9361-55)

FreAmine III 10%, 1000 mL (NDC 00264-9010-55)

Specialty Amino Acid Solutions FreAmine HBC 6.9%, 750 mL (NDC 00264-9350-55)

NephrAmine 5.4%, 250 mL (NDC 00264-1909-55)

HepatAmine 8%, 500 mL (NDC 00264-9371-55)

Baxter Customer Service:
1-800-262-3784

Travasol 10%, 500 mL (NDC 00338-0644-03)
Travasol 10%, 1000 mL (NDC 00338-0644-04)
Travasol 10%, 2000 mL (NDC 00338-0644-06)

Prosol 20%, 2000 mL, sulfite-free (NDC 00338-0499-06)

Clinisol 15%, 500 mL, sulfite-free (NDC 00338-0502-03)
Clinisol 15%, 2000 mL, sulfite-free (NDC 00338-0502-06)

Premasol 6%, 500 mL, sulfite-free (NDC 00338-1131-03)
Premasol 10%, 500 mL, sulfite-free (NDC 00338-1130-03)
Premasol 10%, 1000 mL, sulfite-free (NDC 00338-1130-04)
Premasol 10%, 2000 mL, sulfite-free (NDC 00338-1130-06)

Hepatosol 8%, 500 mL (NDC 00338-0504-03)

CLINIMIX sulfite-free (2.75%, 4.25%, 5.0% Amino Acid in Dextrose) Injections in 1000 mL and 2000 mL Containers

CLINIMIX E sulfite-free (2.75%, 4.25%, 5.0% Amino Acid with Electrolytes in Dextrose with Calcium) Injections in 1000 mL and 2000 mL Containers

Premasol products available

Hepatosol product available

Clinimix and Clinimix E products are available

Baxter is currently experiencing a backorder situation on all presentations of Prosol and Clinisol due to unforeseen demand. Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.

Reverified

3/2/2012

Hospira, Inc.  Customer Service:
1-877-946-7747

5 mEq/mL; 20 mL vial

(NDC 0409-6043-01) 

Other manufacturer shortages/market withdrawal.

Product 5 mEq/mL; 20 mL vial (NDC 0409-6043-01):  company estimates a release date by June 2012.

Please check with your wholesaler for available inventory.

Ucyclyd Pharma, Inc. 1-888-829-2593, or 1-800-900-6389 with a representative available 24 hours, seven days a week.
phone

Limited supplies continue to be available.

Please see attached Dear Healthcare Professional Letter (PDF - 66KB) for important safety information.

Adderall XR capsules
5 mg - 100 count (NDC 54092-0381-01); 10 mg - 100 count (NDC 54092-0383-01); 15 mg - 100 count (NDC 54092-0385-01); 20 mg - 100 count (NDC 54092-0387-01); 25 mg - 100 count (NDC 54092-0389-01); 30 mg - 100 count (NDC 54092-0391-01)

5 mg - 100 count (NDC 00555-0790-02); 10 mg - 100 count (NDC 00555-0787-02); 15 mg - 100 count (NDC 00555-0791-02); 20 mg - 100 count (NDC 00555-0788-02); 25 mg - 100 count (NDC 00555-0792-02); 30 mg - 100 count (NDC 00555-0789-02)

10 mg ,100 count (NDC 00115-1329-01); 15 mg, 100 count (NDC 00115-1330-01); 20 mg, 100 count (NDC 00115-1331-01); 25 mg, 100 count (NDC 00115-1332-01); 30 mg, 100 count (NDC 00115-1333-01)

5 mg tablets, 100 count (NDC 00185-0084-01)

10 mg tablets, 100 count (NDC 00185-0111-01)

20 mg tablets, 100 count (NDC 00185-0401-01)

30 mg tablets, 100 count (NDC 00185-0404-01)

5 mg tablets, 100 count (NDC 64720-0130-10)

10 mg tablets, 100 count (NDC 64720-0132-10)

20 mg tablets, 100 count (NDC 64720-0135-10)

30 mg tablets, 100 count (NDC 64720-0136-10)

5 mg tablets, 100 count (NDC 00555-0971-02)

7.5 mg tablets, 100 count (NDC 00555-0775-02)

10 mg tablets, 100 count (NDC 00555-0972-02)

12.5 mg tablets, 100 count (NDC 00555-0776-02)

15 mg tablets, 100 count (NDC 00555-0777-02)

20 mg tablets, 100 count (NDC 00555-0973-02)

30 mg tablets, 100 count (NDC 00555-0974-02)

Adderall, 5 mg tablets, 100 count (NDC 00555-0762-02)

7.5 mg tablets, 100 count (NDC 00555-0763-02)

10 mg tablets, 100 count (NDC 00555-0764-02)

12.5 mg tablets, 100 count (NDC 00555-0765-02)

15 mg tablets, 100 count (NDC 00555-0766-02)

20 mg tablets, 100 count (NDC 00555-0767-02)

30 mg tablets, 100 count (NDC 00555-0768-02)

50 mg (bottles of 100) - NDC 68220-055-10

50,000 units/mL, 2 mL ampule (NDC 61703-418-07)

10 mg/mL, 5 mL vial, single dose vial (NDC 55390-0102-05)

10 mL vial, multi-dose vial (NDC 55390-0103-10)

5 mL Novaplus vial, single dose vial (NDC 55390-0180-05)

10 mL Novaplus vial, multi-dose vial (NDC 55390-0179-10)

0.1 mg/mL, 10 mL, Luer-Jet Prefilled Syringe
(NDC 00548-339-00)

0.1 mg/mL; 10 mL Ansyr syringe
(NDC 0409-1630-10)

0.05 mg/mL; 5 mL Ansyr syringe
(NDC 0409-9630-05)

0.1 mg/mL; 5 mL Lifeshield syringe
(NDC 0409-4910-34)

0.1 mg/mL; 10 mL Lifeshield syringe
(NDC 0409-4911-34)

Product 0.1 mg/mL; 10 mL Ansyr syringe (NDC 0409-1630-10): ample levels of inventory to support market demand.

Product 0.05 mg/mL; 5 mL Ansyr syringe (NDC 0409-9630-05): next delivery April.

Product 0.1 mg/mL; 5 mL Lifeshield syringe (NDC 0409-4910-34): currently product is available.

Product 0.1 mg/mL; 10 mL Lifeshield syringe (NDC 0409-4911-34): currently product is available. Please check with your wholesaler for available inventory.

Reverified

3/2/2012

0.4 mg/mL, 0.5 mL ampule, package of 25
(NDC 00517-0805-25)

0.4 mg/mL, 1 mL single-dose vial, package of 25
(NDC 00517-0401-25)

1 mg/mL, 1 mL single-dose vial, package of 25
(NDC 00517-1010-25)

1 mg/mL, 1 mL ampule, package of 25 (NDC 00517-0101-25)

American Regent anticipates to have lots available end of April 2012.
 

0.4 mg/mL, 20 mL vial
(NDC 10019-250-20)

West-Ward is currently experiencing a backorder situation on the 0.4 mg/mL, 20 mL vial.

West-Ward has accelerated production on this product and is projecting to have additional inventory available by middle of March 2012.

Product will be made available as it is release.

0.6MG/5ML, 4 fl.oz (NDC: 0085-0942-05)

Hospira, Inc.
Customer Service
1-877-946-7747

0.25%; 30 mL amp
(NDC 0409-1158-01)

0.25%; 10 mL vial
(NDC 0409-1159-01)

0.25%; 30 mL vial
(NDC 0409-1159-02)

0.25%; 50 mL vial
(NDC 0409-1160-01)

0.5%; 10 mL vial
(NDC 0409-1162-01)

0.5%; 30 mL vial
(NDC 0409-1162-02)

0.75%; 10 mL vial
(NDC 0409-1165-01)
 

0.75%; 30 mL vial
(NDC 0409-1165-02)

0.25% w/epi 1:200,000; 10 mL vial
(NDC 0409-9042-01)

0.25% w/epi 1:200,000; 30 mL vial
(NDC 0409-9042-17)

0.25% w/epi 1:200,000; 50 mL
(NDC 0409-9043-01)

0.5% w/epi 1:200,000; 10 mL vial
(NDC 0409-9045-01)

0.5% w/epi 1:200,000; 30 mL vial
(NDC 0409-9045-17)

0.5% w/epi 1:200,000; 50 mL vial
(NDC 0409-9046-01)

50 mg/20 mL Sterile pack amp

(NDC 0409-4272-01)

Product 0.25%; 30 mL amp (NDC 0409-1158-01): next delivery April.
Product 0.5%; 30 mL amp (NDC 0409-1161-01): next delivery May.

Product 0.25%; 10 mL vial (NDC 0409-1159-01): next delivery March.

Product 0.25%; 30 mL vial (NDC 0409-1159-02): next delivery March.

Product 0.25%; 50 mL vial (NDC 0409-1160-01): next delivery March.

Product 0.5%; 10 mL vial (NDC 0409-1162-01): next delivery March.

Product 0.5%; 30 mL vial (NDC 0409-1162-02): next delivery April.

Product 0.5%; 50 mL vial (NDC 0409-1163-01): next delivery March.

Product 0.75%; 10 mL vial (NDC 0409-1165-01): next delivery March.

Product 0.75%; 30 mL vial (NDC 0409-1165-02): next delivery March.

Products 0.75% w/ dextrose 8.25%; 2 mL ampule (NDC 0409-3613-01): next delivery March.

Product 0.25% w/epi 1:200,000; 10 mL vial (NDC 0409-9042-01): next delivery May.

Product 0.25% w/epi 1:200,000; 30 mL vial (NDC 0409-9042-17): next delivery April.

Product 0.25% w/epi 1:200,000; 50 mL vial (NDC 0409-9043-01): next delivery April.

Product 0.5% w/epi 1:200,000; 10 mL vial (NDC 0409-9045-01): next delivery April.

Product 0.5% w/epi 1:200,000; 30 mL vial (NDC 0409-9045-17): next delivery April.

Product 0.5% w/epi 1:200,000; 50 mL vial (NDC 0409-9046-01): next delivery April.

Product 50 mg/20 mL Sterile pack amp (NDC 0409-4272-01) next delivery March.

Product 0.25%; 20 mL amp (NDC 0409-5622-01): next delivery March.

Product 0.5%; 20 mL Sterile pack amp (NDC 0409-4273-01): next delivery March.

Please check with your wholesaler for available inventory.

1 mL vial (NDC 55390-0010-10)

1 mL Carpuject syringe (NDC 00409-2012-32

Reverified

3/2/2012

1 mL vial (NDC 00517-0725-05)

Buprenex 0.3 mg/mL 1 mL ampules (NDC 12496-0757-01)

Hospira, Inc.
Customer Service:
1-877-946-7747

1 mg/mL; 1 mL vial

(NDC 0409-1623-01)

2 mg/mL; 1 mL vial

(NDC 0409-1626-01)

2 mg/mL; 2 mL vial

(NDC 0409-1626-02)

Product 1 mg/mL; 1 mL vial (NDC 0409-1623-01): next delivery April.

Product 2 mg/mL; 1 mL vial (NDC 0409-1626-01): next delivery March.

Product 2 mg/mL; 2 mL vial (NDC 0409-1626-02: next delivery April.

Please check with your wholesaler for all available inventory.

1 mg/mL 1 mL vial (NDC 55390-0183-01)
1 mg/mL 1 mL Novaplus vial (NDC 55390-0341-10)
2 mg/mL 1 mL vial (NDC 55390-0184-01)
2 mg/mL 2 mL vial (NDC 55390-0184-02)
2 mg/mL 1 mL Novaplus vial (NDC 55390-0342-10)
2 mg/mL 10 mL vial (NDC 55390-0185-10)

2 mL single-dose vial, package of 10 (NDC 00517-2502-10)

100 mg caffeine/ 1 mg ergotamine tartrate; 100 count bottle (NDC 00781-5405-01

1 mcg/mL; 1 mL ampule, 25 count (NDC 00517-0132-25)

Revised

3/19/2012

1 mcg/ml; 1 mL ampule, 50 count (NDC 63323-0731-01

1 mL ampule, 5 count (NDC 00143-9728-05)

Akorn 1 mL ampule, 10-pack (NDC 17478-0931-01)

Product releases scheduled for March and April to support market demand.

Revised 

3/16/2012

Hospira Inc.
1-877-946-7747

100 mg/mL; 10 mL Abboject

(NDC 0409-4928-34)

100 mg/mL; 10 mL Ansyr

(NDC 0409-1631-10)

Product 100 mg/mL; 10 mL Abboject (NDC 0409-4928-34):  next delivery March.

Product 100 mg/mL; 10 mL Ansyr (NDC 0409-1631-10):  next delivery March.

Please check with your wholesaler for available inventory.

10%,  10 mL vial
NDC 0517-2710-25

100 mg/mL vials, 10 mL vials (NDC 63323-0311-10) 50 mL vials (NDC 63323-0311-50) 100 mL vials (NDC 63323-0311-61)

Revised

3/12/2012

100 mg/mL; 50 mL (NDC 00517-3950-25) vials

100 mg/mL; 100 mL NDC (00517-3900-25) vials

Capastat, lyophilized powder for injection
1 gram vial (NDC 17478-0080-50

For inquiries contact Genzyme Medical Information: This e-mail address is being protected from spambots. You need JavaScript enabled to view it or 800-745-4447, option 2

Please see the Dear U.S. Healthcare Provider Letter (PDF - 105KB).

Starting in February 1, 2012, Genzyme has been providing full supply for patients in the U.S. who are currently receiving Cerezyme.

4 mcg/mL; 10 mL vial
(NDC 0409-4093-01)

Product 4 mcg/mL; 10 mL vial (NDC 0409-4093-01):  next delivery April.

Reverified

3/2/2012

SOL 4 mcg/ml INTRAVENOUS 10 ml 25s (NDC 00517-6310-25)

Revised

3/12/2012

EQ 0.1 MG Base/Vial (NDC 55566-0302-1)

0.25mg/ml (NDC 10139-0905-02); packages of 10 (NDC 10139-0905-10)

0.25mg/ml (NDC 00871-23052-71); Package of 10 (NDC 00781-3052-95)

5 mg/mL, 4 mL single-dose vial (NDC 00703-5233-13)

Reverified

3/15/2012

Bedford Customer Service
1-800-562-4797

5 mg/mL, 4 mL single-dose vial (NDC 55390-0108-10)

10 mL single-dose vial (NDC 55390-0108-01)

Cerubidine lyophilized powder for injection, 20 mg single-dose vial, package of 10 (NDC 55390-0281-10)

The company cannot estimate a future release date for more product.

4 mcg/mL 1ml vials (NDC 55566-5030-01) and 4mcg/mL 10ml (NDC 55566-5040-01)

Manufacturing delay

Ferring currently has no inventory of the 10 mL vial available (NDC 55566-5040-01)
Ferring currently has no inventory of the 1 mL ampoules (NDC 0409-2265-01)

The firm anticipates additional limited inventory of the ampoules in March 2012. 
The firm anticipates additional limited inventory of the 10 mL vials in May 2012.

Revised

3/16/2012

4 mcg/mL, 1 mL amp (NDC 00409-2265-01)

Product 4 mcg/mL; 1 mL amp (NDC 0409-2265-01):  next delivery March 2012.

Please check with your wholesaler for available inventory.

Reverified

3/2/2012

(DDAVP) 4 mcg/mL;  1 mL  ampule (NDC 00075-2451-01)
4 mcg/mL; 10 mL vial (NDC 00075-2451-53)

(4 mcg/mL, 1 mL vial, 10 count (NDC 00703-5051-03) 10 mL multi-dose vial (NDC 00703-5054-01)).

4 mg/mL; 1 mL SDV (NDC 0517-4901-25), 5 mL MDV (NDC 0517-4905-25); 30 mL MDV (NDC 0517-4930-25)

10 mg/ml; 1 mL vial
(NDC 0641-0367-25)

Revised

3/12/2012

Pfizer Injectables is 1-800-533-4535

Dexamethasone Sodium Phosphate Injection, 4 mg/mL

1 mL vial (NDC 00069-4547-02)
5 mL vial (NDC 00069-4543-02)

Dexrazoxane for injection
250 mg and 500mg

250 mg vial (NDC 67457-0207-25)

500 mg vial (NDC 67457-208-50)

Reverified

3/15/2012

http://www.pfizerinjectables.com/

Totect 500 mg (dexrazoxane) for injection
(NDC 38423-110-01)

Limited supplies available at Cardinal, McKesson Specialty and Morris & Dickson each have 2 kits a piece (total 6 kits). Please check with these wholesalers directly for available inventory. Out of stock at ICS, ASD Healthcare, Oncology Supply and US Oncology.

Topotarget USA, Inc. has product on back order and the company cannot estimate a release

5 mg tablets, 100 count (NDC 00555-0952-02)
10 mg tablets, 100 count (NDC 00555-0953-02)

5 mg/mL; 2 mL Carpuject (0409-1273-32)

5 mg/mL; 10 mL vial
(0409-3213-12)

Manufacturing delay.

250 mcg/mL, 2 mL ampuls (NDC 0641-1410-35)

West-Ward is currently experiencing a backorder situation on the 2 mL ampul.

Production has been accelerated and several additional lots are scheduled to be released by the end of March 2012.

Product will be made available as it is released.

Revised

3/12/2012

USP 0.25 mg/mL, 2 mL (NDC 0781-3059-95)

Covis Pharma S.à.r.l Customer Service:
866-488-4423

Lanoxin Injection, USP 250 mcg/mL, 2 mL (10s - NDC 00173-0260-10)

Lanoxin Injection, USP 250 mcg/mL, 2 mL (50s - NDC 00173-0260-35)

Lanoxin Injection 250 mcg/mL, 2 mL (10s - NDC 00173-0260-10) is currently available in limited quantities through March 2012 with full availability expected in April 2012.

Covis Pharma S.à.r.l has discontinued manufacturing Lanoxin Injection, USP 250 mcg/mL, 2 mL (50s - NDC 00173-0260-35).

West-Ward Pharmaceuticals Customer Service
1-888-229-0001

(Formerly a Baxter Product)

5 mL vial (NDC 10019-510-01) 10 mL vial (NDC 10019-510-02)

25 mL vial (NDC 10019-510-04)

5 mL vial (NDC 10019-510-01) Additional product releases expected later this month and at the end of May.

10 mL vial (NDC 10019-510-02) - Product will be available end of May

25 mL vial (NDC 10019-510-04) - Product releases expected by mid April and end of May.

Product will be made available as it is released.

5 mg/mL, 5 mL vials

(NDC 00409-1171-01)

5 mg/mL, 10 mL vials

(NDC 00409-1171-02)

100 mg/mL, ADD-Vantage vials (NDC 00409-4350-03)

Other Manufacturer Shortages/Market Withdrawal

Product 5 mg/mL; 5 mL vial (NDC 0409-1171-01): next delivery March.

Product 100 mg/mL; ADD-Vantage vial (NDC 0409-4350-03): ample supply available.

Product 5 mg/mL; 10 mL vial (NDC 0409-1171-02): next delivery March.

Please check with your wholesaler for available inventory.

5 mg/mL 5 mL vials (NDC 55390-0565-05), 5 mg/mL 10 mL vials (NDC 55390-0565-10)

5 mg/mL 25 mL vials (NDC 55390-0565-30), 5 mg/mL 5 mL Novaplus vials (NDC 55390-0566-05)

5 mg/mL 10 mL Novaplus vials (NDC 55390-0566-10), 5 mg/mL 25 mL Novaplus vials (NDC 55390-0566-30)

5 mg/mL, 25 mL vials (NDC 17478-0937-25)

Revised 

3/16/2012

50 mg/ml, 1 ml (NDC 63323-0664-01)

Revised

3/12/2012

50 mg/mL; 1 mL Carpuject (NDC 0409-2290-31)

Product 50 mg/mL; 1 mL Carpuject (NDC 0409-2290-31): next delivery June 2012.

Reverified

3/2/2012

50 mg/ml, 10 ml, 10s
(NDC 67457-0124-10)

Reverified

3/15/2012

50 mg/mL, 1 mL vial
(NDC 0641-0376-25)

West-Ward is currently experiencing a backorder situation on the 50 mg/mL, 1 mL vial.

West-Ward has accelerated production on this product and is projecting availability of additional units by the end of March – beginning of April 2012.

Product will be made available as it is released.

Revised

3/15/2012

10 mg vials (NDC 55390-0231-01)

20 mg vials (NDC 55390-0232-10)

50 mg vial (NDC 55390-0233-01)

Doxil 2 mg/mL, Janssen Products, LP
2 mg/mL, 10 mL (20 mg) vial (NDC 59676-0960-01)
2 mg/mL, 25 mL (50 mg) vial (NDC 59676-0960-02)

Please see http://www.doxil.com/sites/default/files/DHCP_september2011.pdf  for additional information.

Important Updates on DOXIL Supply Shortage

Sun Pharma Global FZE, and its authorized distributor, Caraco Pharmaceutical Laboratories Ltd, in conjunction with the FDA, are initiating a temporary importation of Lipodox (doxorubicin HCL liposomal for injection), into the United States market to address this shortage. Please see the Dear Healthcare Professional Letter (PDF - 65KB) for information about supplies that are now available to help address the current shortage.

Frequently Asked Questions (FAQs) about Sun's Lipodox (doxorubicin HCL liposomal injection) (PDF - 20KB)

Teva Pharmaceuticals
1-800-545-8800

2 mg/mL; 5 mL vial (NDC 00703-5043-03)
2 mg/mL; 25 mL vial (NDC 00703-5046-01)
2 mg/mL; 100 mL vial (NDC 00703-5040-01)

Reverified

3/12/2012

See Dear Healthcare Professional Letter (PDF - 483KB) for additional information.
(Letter updated 3/20/2012)

2 mg/mL vial
10 mL vial (NDC 00517-0780-10)

20 mL vial (NDC 00517-0781-10)

American Regent anticipates to have product available end of March 2012.

2 mg/mL; 10 mL vial (NDC 0409-6695-01)

2 mg/mL; 20 mL vial (NDC 0409-6695-02)

2 mg/mL; 20 mL Abboject syringe (NDC 0409-8060-29)

2 mg/mL; 20 mL amp (NDC 0409-8061-01)

2 mg/mL; 10 mL amp (NDC 0409-8062-01)

Product 2 mg/mL; 20 mL vial (NDC 0409-6695-02): next delivery June.

Product 2 mg/mL; 20 mL Abboject syringe (NDC 0409-8060-29): next delivery June.

Product 2 mg/mL; 20 mL amp (NDC 0409-8061-01): next delivery June.

Product 2 mg/mL; 10 mL amp (NDC 0409-8062-01): next delivery June.
 
Please check with your wholesaler for available inventory.

2 mg/mL injection
10 mL vial
(NDC 55390-0762-10)

20 mL
(NDC 55390-0763-20)

20 mg/10ml injection (NDC 0069-0006-01)

40 mg/20ml injection (NDC 0069-0006-03)

Teva Pharmaceuticals
1-800-545-8800

Toposar
20 mg/ml; 5 mL vial (NDC 00703-5653-01)
20 mg/ml; 25 mL vial (NDC 00703-5656-01)
20 mg/ml; 50 mL vial (NDC 00703-5657-01)

APP
1-888-386-1300
 
20 mg/mL; 5 mL vial (NDC 63323-0104-05)

20 mg/ml; 25 mL vial (NDC 63323-0104-25)

20 mg/ml;50 mL vial (NDC 63323-0104-50) 

Revised

3/12/2012

100mg/5mL, 5mL vial (NDC#16729-114-31)

For inquiries contact Genzyme Medical Information: This e-mail address is being protected from spambots. You need JavaScript enabled to view it or 800-745-4447, option 2

Starting in March 1, 2012, patients in the U.S. who are currently receiving treatment with Fabrazyme will be able to return to full dose.  We are also transitioning patients from our current waiting list in the U.S. to treatment with Fabrazyme at full dose as quickly as possible.

0.05 mg/mL; 2 mL Carpuject
(0409-1276-32)

0.05 mg/mL; 2 mL amp
(0409-9093-32)

0.05 mg/mL; 5 mL amp
(0409-9093-35)

0.05 mg/mL; 20 mL amp
(0409-9093-38)

0.05 mg/mL; 2 mL vial
(0409-9094-22)

0.05 mg/mL; 5 mL vial
(0409-9094-25)

0.05 mg/mL; 10 mL vial
(0409-9094-28)

0.05 mg/mL; 20 mL vial
(0409-9094-31)

0.05 mg/mL; 50 mL vial
(0409-9094-61)

Product 0.05 mg/mL; 5 mL amp (0409-9093-35): next anticipated delivery March.

Product 0.05 mg/mL; 20 mL amp (0409-9093-38): next anticipated delivery March.

Product 0.05 mg/mL; 2 mL vial (0409-9094-22): next anticipated delivery May.

Product 0.05 mg/mL; 5 mL vial (0409-9094-25): next anticipated delivery May.

Product 0.05 mg/mL; 10 mL vial (0409-9094-28): next anticipated delivery May.

Product 0.05 mg/mL; 20 mL vial (0409-9094-31): next anticipated delivery May.

Product 0.05 mg/mL; 50 mL vial (0409-9094-61): next anticipated delivery May.

Fentanyl products listed above must be ordered through the wholesaler; check with your wholesaler regarding product allocation. It is recommended that the user institute fentanyl sparing strategies.

Product 0.05 mg/mL; 2 mL Carpuject (0409-1276-32): next delivery March.

Carpuject orders (NDC 0409-1276-32) may be placed direct or through the wholesaler, and will be filled in the order in which received.

Revised

3/5/2012

50 mcg/mL

2 mL ampul
(NDC 10019-038-67)

5 mL ampul
(NDC 10019-033-72)

20 mL ampul
(NDC 10019-035-74)

2 mL vial
(NDC 10019-037-27)

5 mL vial
(NDC 10019-037-30)

20 mL vial
(NDC 10019-037-25)

50 mL vial
(NDC 10019-037-83)

West-Ward is currently experiencing a backorder situation on most presentations due to market demand.  There are limited quantities currently available of the 5 mL and 20 mL vials.

West-Ward has accelerated production on all codes and will have the following products available:
Multiple lots of the 2 mL, 5 mL, and 20 mL ampuls are anticipated to be released and available in the April - May 2012 timeframe.

Lots of the 2 mL, 5 mL, 20 mL, and 50 mL vials are scheduled to be manufactured and available for release in the March - April 2012 timeframe.

Product will be made available as it is released.

Revised

3/13/2012

2 mL (NDC 1748-0030-02)

5 mL (NDC 1748-0030-05)

20 mL (NDC 1748-0030-20)

20 mL releasing early April.

Increased production available, contingent on market demand.

Revised

3/16/2012

Teva Pharmaceuticals
1-800-545-8800

50 mg/mL; 10 mL vial (NDC 00703-3015-13)
50 mg/mL; 50 mL vial (NDC 00703-3018-12)
50 mg/mL; 100 mL vial (NDC 00703-3019-12)

APP
1-888-386-1300

50 mg/ml; 10 mL vial (NDC 63323-0117-10)
50 mg/ml; 20 mL vial (NDC 63323-0117-20)
 
50 mg/mL; 50 mL vial (NDC 63323-0117-51)
50 mg/mL; 100 mL vial (NDC 63323-0117-61)

Revised

3/12/2012

24 mg/mL; 250 mL bottle
(NDC 0409-3863-02)

24 mg/mL; 500 mL bottle
(NDC 0409-3863-05)

75 mg/mL; 2 mL vial
(NDC 0409-4857-02)

75 mg/mL; 50 mL vial
(NDC 0409-4857-10)

American Regent/Luitpold
1-800-645-1706

75 mg/mL (50 mg PE/mL); 2 ml vial, 25 count (NDC 00517-6902-25)

Reverified

3/19/2012

Teva Pharmaceuticals
1-800-545-8800

50 mg/mL, 1 mL vial (NDC 00703-7011-03)
50 mg/mL, 5 mL vial (NDC 00703-7013-01)
100 mg/mL, 1 mL vial (NDC 00703-7021-03)
100 mg/mL, 5 mL vial (NDC 00703-7023-01)

Revised

3/12/2012

Patriot Pharmaceuticals, LLC.
1-800-631-5273

50 mg/mL Injection, 1 mL Ampules (NDC: 10147-0921-3)

100 mg/mL Injection, 1 mL Ampules (NDC: 10147-0922-5)

HELIDAC (bismuth subsalicylate/tetracycline hydrochloride/metronidazole) Therapy

(NDC 65483-495-14)

10 mg/mL, 1 mL vials (NDC 00703-0110-03)

10 mg/mL, 5 mL vials (NDC 00703-0113-03)

10 mg/mL, 50 mL vials (NDC 00703-0118-01)

Reverified

3/15/2012

2 mg/mL, 1 mL vials (NDC 00641-0121-25)

2 mg/mL, 20 mL multi-dose vials (NDC 00641-2341-41)

West-Ward is currently experiencing a backorder situation on both presentations.

West-Ward has increased production and is anticipating having several lots of the 1 mL vial released and available by the end of March 2012.  Additional lots are scheduled for production in the April – May 2012 timeframe. 

Several lots of the 20 mL vial will also be available by the middle of April 2012.

Product will be made available as it is released.

Akorn Pharmaceuticals
1-800-932-5676

10 mg/mL, 1 mL ampules (NDC 17478-0540-01)

10 mg/mL, 5 mL ampules (NDC 17478-0540-05)

10 mg/mL, 50 mL vials (NDC 17478-0540-50)

5 mL ampoule (NDC 17478-0540-05)-Releasing mid-April

50 mL vial (NDC 17478-0540-50)-Readily available
 

Revised 

3/16/2012

1 mg/mL, 1 mL ampules, package of 10 (NDC 59011-0441-10)

2 mg/mL, 1 mL ampules, package of 10 (NDC 59011-0442-10)
2 mg/mL, 1 mL ampules, package of 25 (NDC 59011-0442-25)
4 mg/mL, 1 mL ampules, package of 10 (NDC 59011-0444-10)

Dilaudid-HP injection
250 mg vial, powder for injection (NDC 59011-0446-25)
10 mg/mL, 1 mL ampules (NDC 59011-0445-01)
10 mg/mL, 5 mL ampules (NDC 59011-0445-05)
10 mg/mL, 50 mL vials (NDC 59011-0445-50

All other products are available.

Revised 

3/12/2012

8 mg/mL, 5 mL ampule
(NDC 17478-0508-01)

5 mL (NDC 17478-0508-01)-Readily available

8 mg/mL, 5 mL ampule
(NDC 00517-0375-10)

Dear Healthcare Professional Letter (PDF - 21KB)

Liposyn III (fatemulsion/soybean oil)

10%; 250 mL (NDC 0409-9790-02)

10%; 500 mL (NDC 0409-9790-03)

20%; 250 mL (NDC 0409-9791-02)

20%; 500 mL (NDC 0409-9791-03)

30%; 500 mL (NDC 0409-6892-03)

(300 mg - 30s - 00555-0071-01, 100s - 00555-0071-02, 1000s - 00555-0071-05; 100mg - 100s - 00555-0066-02, 1000s - 00555-0066-05)

(300 mg - 30s - 00185-4350-30, 100s - 00185-4350-01, 1000s - 00185-4350-10; 100mg - 30s - 00185-4351-30, 100s - 00185-4351-01, 1000s - 00185-4351-10)

100 mg product currently available

300 mg product available around july 2012

(300 mg - 30s - 61748-0013-30, 100s - 61748-0013-01, 1000s - 61748-0013-10; 100mg - 100s - 61748-0016-01)

Bedford Customer Service
1-800-562-4797

15 mg/mL 1 mL vial, 10 count (NDC 55390-0480-01)

30 mg/mL 1 mL vial, 10 count (NDC 55390-0481-01)

30 mg/mL 10 mL vial, 10 count (NDC 55390-0481-10)

Manufacturing delays

Reverified

3/19/2012

Wockhardt

30 mg/mL 1 mL vial, 10 count (NDC 64679-0758-04)

30 mg/mL 2 mL vial, 10 count (NDC 64679-0758-06)

30 mg/mL 2 mL vial, 25 count (NDC 64679-0758-02)

Revised

3/9/2012

APP
1-888-386-1300

15 mg/mL 1 mL vial, 25 count (NDC 63323-0161-01)

30 mg/mL 1 mL vial, 25 count (NDC 63323-0162-01)

30 mg/mL 2 mL vial for intramuscular injection, 25 count (NDC 63323-0162-02)

Hospira, Inc.
Customer Service
1-877-946-7747

15 mg/mL; 1 mL vial
(NDC 0409-3793-01)

15 mg/mL; 1 mL Carpuject
(NDC 0409-2288-31)

30 mg/mL; 1mL vial
(NDC 0409-3795-01)

30 mg/mL; 1 mL Carpuject
(NDC 0409-2287-31)

30 mg/mL; 2 mL Carpuject
(NDC 0409-2287-61)

60 mg/mL; 2 ml vial
(NDC 0409-3796-01)

Higher than anticipated market demand; Manufacturing delay.

Product 30 mg/mL; 1mL vial (NDC 0409-3795-01): next delivery March.
 
Product 30 mg/mL; 1 mL Carpuject(NDC 0409-2287-31): next delivery April.
 
Product 60 mg/mL; 2 ml vial (NDC 0409-3796-01):  next delivery March.
 
NOTE:  Products 30 mg/mL; 2 mL Carpuject (NDC 0409-2287-61) and 15 mg/mL; 1 mL Carpuject (NDC 0409-2288-31):  suspended production until 2013 due to manufacturing line prioritization.

Revised

3/12/2012

1 mg/0.2 ml (NDC 00703-4014-18)

Reverified

3/15/2012

1 mg/0.2 ml (NDC 00185-7400-85)

Reverified

3/16/2012

1 mg/0.2 ml (NDC 41616-0936-40)

25 mg/mL, 20 mL vial (NDC 17478-0107-20)

25 mg/mL, 30 mL vial (NDC 17478-0107-30)

Revised

3/16/2012

250 mg_50 mL Premix Bag NDC 25021-132-81

500 mg_100 mL Premix Bag NDC 25021-132-82

750 mg_150 mL Premix Bag NDC 25021-132-83

Sagent has both presentations of the Levofloxacin Injection vials available.

Sagent has all 3 strengths for premix bags available for contracted customers only

250 mg in 50 mL Dextrose 5%, premix bag (NDC 00781-3341-09)

500 mg in 100 mL Dextrose 5%, premix bag (NDC 00781-3342-09)

750 mg in 150 mL Dextrose 5%, premix bag (NDC 00781-3343-09)

Reminder: There is potential for dosing errors when interchanging leucovorin and levoleucovorin (Fusilev). The dose of levoleucovorin (Fusilev) is one-half the dose of racemic leucovorin injection (e.g., levoleucovorin [Fusilev] 7.5 mg = racemic leucovorin 15 mg).

For more information visit: Spectrum Pharmaceuticals  web site. 

Lidocaine 0.5%
Xylocaine 0.5% injection
5 mg/mL, 50 mL vial (NDC 63323-0484-57)

Xylocaine 0.5% - MPF injection, APP
5 mg/mL, 50 mL vial (NDC 63323-0491-57)

Lidocaine 1%
Lidocaine 1% injection
10 mg/mL, 2 mL vial (NDC 63323-0201-02)
10 mg/mL, 10 mL vial (NDC 63323-0201-10)

Xylocaine 1% injection
10 mg/mL, 20 mL vial (NDC 63323-0485-27)
10 mg/mL, 50 mL vial (NDC 63323-0485-57)

Xylocaine 1% - MPF injection
10 mg/mL, 2 mL vial (NDC 63323-0492-27)
10 mg/mL, 2 mL glass ampule (NDC 63323-0492-80)
10 mg/mL, 5 mL glass ampule (NDC 63323-0492-89)
10 mg/mL, 5 mL vial (NDC 63323-0492-57)
10 mg/mL, 30 mL vial (NDC 63323-0492-37)
10 mg/mL, 30 mL vial, sterile pack (NDC 63323-0492-31)

Lidocaine 1.5%
Xylocaine 1.5% - MPF injection
15 mg/mL, 10 mL ampule (NDC 63323-0493-97)
15 mg/mL, 20 mL ampule (NDC 63323-0493-91)

Lidocaine 2%
Lidocaine 2% injection
20 mg/mL, 2 mL vial (NDC 63323-0202-02)
20 mg/mL, 5 mL SD Tear Top vial, preservative-free (NDC 63323-0208-05)

Xylocaine 2% injection
20 mg/mL, 10 mL vial (NDC 63323-0486-17)
20 mg/mL, 20 mL vial (NDC 63323-0486-27)
20 mg/mL, 50 mL vial (NDC 63323-0486-57)
20 mg/mL, 10 mL vial (NDC 63323-0486-10) – NDC discontinued
20 mg/mL, 20 mL vial (NDC 63323-0486-20) – NDC discontinued
20 mg/mL, 50 mL vial (NDC 63323-0486-50) – NDC discontinued

Xylocaine 2% - MPF injection
20 mg/mL, 2 mL vial (NDC 63323-0495-27)
20 mg/mL, 5 mL vial (NDC 63323-0495-07)
20 mg/mL, 10 mL ampule (NDC 63323-0496-97)

0.5% w/EPI 1:200,000; 50 mL vial (NDC 0409-3177-01)

1% w/EPI 1:100,000; 50 mL vial (NDC 0409-3178-03)

1.5% w/EPI 1:200,000; 5 mL amp (NDC 0409-1209-65)

2% w/EPI 1:100,000; 20 mL vial (NDC 0409-3182-01)

2% w/EPI 1:100,000; 30 mL vial (NDC 0409-3182-02)

2% w/EPI 1:100,000; 50 mL vial (NDC 0409-3182-03)

.0.5%; 50 mL FT  vial (NDC 0409-4275-01)

0.5%; 50 mL TT vial (NDC 0409-4278-01)

1%; 2 mL amp (NDC 0409-4713-32)

1%; 5 mL amp (NDC 0409-4713-02)

1%; 20 mL vial (NDC 0409-4276-01)

1%; 30 mL vial (NDC 0409-4279-02)

1%; 50 mL vial (NDC 0409-4276-02)

1%; 30 mL Sterile Pack vial (NDC 0409-4270-01)

2%; 2 mL amp(NDC 0409-4282-01)

2%; 10 mL amp (NDC 0409-4282-02)

2%; 5 mL vial (NDC 0409-2066-05)

2%; 20 mL vial (NDC 0409-4277-01)

2%; 50 mL vial (NDC 0409-4277-02)

4%; 5 mL amp (NDC 0409-4283-01)

Product 1% w/EPI 1:100,000; 50 mL vial (NDC 0409-3178-03): next delivery March.

Product 1.5% w/EPI 1:200,000; 5 mL amp (NDC 0409-1209-65): next delivery March.

Product 2% w/EPI 1:100,000; 20 mL vial (NDC 0409-3182-01): ample supply available

Product 2% w/EPI 1:100,000; 30 mL vial (NDC 0409-3182-02): next delivery March.

Product 2% w/EPI 1:100,000; 50 mL vial (NDC 0409-3182-03): next delivery March.

Product 0.5%; 50 mL FT vial (NDC 0409-4275-01): next delivery March.

Product 0.5%; 50 mL TT vial (NDC 0409-4278-01): next delivery March.

Product 1%; 2 mL amp (NDC 0409-4713-32): next delivery April.

Product 1%; 5 mL amp (NDC 0409-4713-02): next delivery March.

Product 1%; 20 mL vial (NDC 0409-4276-01): next delivery March.

Product 1%; 30 mL vial (NDC 0409-4279-02): next delivery March.

Product 1%; 50 mL vial (NDC 0409-4276-02): next delivery March.

Product 1%; 30 mL Sterile Pack vial (NDC 0409-4270-01): next delivery March.

Product 2%; 2 mL amp (NDC 0409-4282-01): next delivery May.

Product 2%; 10 mL amp (NDC 0409-4282-02): next delivery April.

Product 2%; 5 mL vial (NDC 0409-2066-05): next delivery April.

Product 2%; 20 mL vial (NDC 0409-4277-01): next delivery March.

Product 2%; 50 mL vial (NDC 0409-4277-02): next delivery March.

Product 4%; 5 mL amp (NDC 0409-4283-01): next delivery April.

1.5%; 20 mL amp (NDC 0409-4776-01): next delivery May.

1.5 %; 20 mL Sterile Pack amp, preservative-free (NDC 0409-4056-01): next delivery March.
2%; 5 mL Ansyr syringe (NDC 0409-1323-05): next delivery March.

Available presentations:
1% w/EPI 1:100,000; 20 mL vial (NDC 0409-3178-01)
1% w/EPI 1:100,000; 30 mL vial (NDC 0409-3178-02)
1.5% w/EPI 1:200,000; 5 mL amp (NDC 0409-1209-01)
2% w/EPI 1:200,000; 20 mL vial (NDC 0409-3183-01)
1%; 5 mL Abboject syringe (NDC 0409-4904-34)
2%; 5 mL Abboject syringe (NDC 0409-4903-34)

Please check with your wholesaler for available inventory.

West-Ward Pharmaceuticals

Customer Service:
1-800-631-2174
(Formerly a Baxter Product)

Ativan (lorazepam) Injection

2 mg/mL, 1 mL vial
(NDC 60977-112-01)

2 mg/mL, 10 mL vial,

(NDC 60977-116-02)

4 mg/mL, 1 mL vial
(NDC 60977-113-01)

4 mg/mL, 10 mL vial,

(NDC 60977-113-02)

Lorazepam Injection, USP

2 mg/mL, 1 mL vial
(NDC 10019-102-01)

2 mg/mL, 10 mL vial,

(NDC 10019-102-10)

4 mg/mL, 1 mL vial
(NDC 10019-103-01)

4 mg/mL, 10 mL vial,

(NDC 10019-103-10)

West-Ward is currently experiencing a backorder situation on all Ativan and Lorazepam codes.  Manufacturing has been increased to meet product demand.

Multiple lots of all codes are projected to be released and available in the late March – April 2012 timeframe.

Product will be made available as it is released.

Revised

3/19/2012

2 mg/mL, 1 mL vial (NDC 55390-0168-10), 10 mL vial (NDC 55390-0170-10)

Hospira Inc. Customer Service:
1-877-946-7747

2 mg/mL; 1 mL vial
(NDC 00409-6778-02)

2 mg/mL; 10 mL vial
(NDC 0409-6780-02)

2 mg/mL; 1 mL Carpuject syringe
(NDC 0409-1985-30)

2 mg/mL; 1 mL iSecure syringe
(NDC 0409-1985-05)
 
4 mg/mL; 1 mL vial
(NDC 0409-6779-02)

4 mg/mL; 10 mL vial
(NDC 0409-6781-02)

4 mg/mL; 1 mL
Carpuject syringe (NDC 0409-1539-31)

Product 2 mg/mL; 10 mL vial (NDC 0409-6780-02): next delivery May.

Product 2 mg/mL; 1 mL Carpuject syringe (NDC 0409-1985-30): next delivery March.

Product 4 mg/mL; 1 mL vial (NDC 0409-6779-02): next delivery in May.

Product 4 mg/mL; 10 mL vial (NDC 0409-6781-02): next delivery in May.

Product 2 mg/mL; 1 mL vial (NDC 0409-6778-02): next delivery in March.

Please note that 4 mg/mL; 1 mL Carpuject syringe (NDC 0409-1539-31) is temporarily unavailable.
Please note that 2 mg/mL; 1 mL iSecure prefilled syringe (NDC 0409-1985-05) has been discontinued.
Please check with your wholesaler for available inventory.

Akorn has Lorazepam injection 2 mg/mL, 1 mL vials on intermittent back order and are filling direct orders and shipping to wholesalers as product becomes available.

Revised

3/16/2012

500 mg/mL, 2 mL vial (NDC 63323-0064-02), 500 mg/mL, 10 mL vial (NDC 63323-0064-10), 500 mg/mL, 20 mL vial (NDC 63323-0064-20), 500 mg/mL, 50 mL vial (NDC 63323-0064-50)

500 mg/mL, 2 mL vial (NDC 00517-2602-25), 500 mg/mL, 10 mL vial (NDC 00517-2610-25), 500 mg/mL, 50 mL vial (NDC 00517-2650-25)

50%; 20 mL vial

(NDC 0409-2168-02)

50 %; 10 mL Ansyr syringe

(NDC 0409-1754-10)

40 mg/mL-water; 50 mL bag

(NDC 0409-6729-24)

40 mg/mL-water; 100 mL bag

(NDC 0409-6729-23)

40 mg/mL-water; 500 mL bag

(NDC 0409-6729-03)

40 mg/mL-water; 1000 mL bag

(NDC 0409-6729-09)

10 mg/mL-dextrose; 100 mL bag

(NDC 0409-6727-23)

80 mg/mL-water; 50 mL bag

(NDC 0409-6730-13)

Product 50 %; 20 mL vial (NDC 0409-2168-02): next delivery March.

Product 50 %; 10 mL Ansyr syringe (NDC 0409-1754-10): next delivery March.

Product 40 mg/mL; 50 mL bag (NDC 0409-6729-24): next delivery March.

Product 40 mg/mL-water; 100 mL bag (NDC 0409-6729-23): next delivery March.

Product 40 mg/mL-water; 500 mL bag (NDC 0409-6729-03): next delivery March.

Product 40 mg/mL-water; 1000 mL bag (NDC 0409-6729-09): next delivery April.

Product 10 mg/mL-dextrose; 100 mL bag (NDC 0409-6727-23): next delivery March.

Product 80 mg/mL-water; 50 mL bag (NDC 0409-6730-13): next delivery March.

Please check with your wholesaler for available inventory.

250 mg/mL, 50 mL vial, 25 count
(NDC 63323-0024-25)

20% Mannitol Injection USP
L5781 500 mL flexible plastic container NDC 0264-7578-10
 
L5782 250 mL flexible plastic container NDC 0264-7578-20

25%; 50 mL vial
(NDC 0409-4031-01)

20%; 250 mL container
(NDC 0409-7715-02)

20%; 500 mL container
(NDC 0409-7715-03)

Product 25%; 50 mL vial (NDC 0409-4031-01): next delivery April.

Product 20%; 250 mL container (NDC 0409-7715-02): next delivery 2012.

Product 20%; 500 mL container (NDC 0409-7715-03): next delivery 2012.

Please check with your wholesaler for all available inventory.

25%,  50 mL vial
NDC 0517-4050-25

Revised

3/19/2012

20% OSMITROL Injection (20% Mannitol Injection, USP). NDC: 0338-0357-02

20% OSMITROL Injection (20% Mannitol Injection, USP). NDC: 0338-0357-03

10 mL vials, 1 count (NDC 25021-0201-10)

10 mL vials, 10 count (NDC 25021-0201-11)

10 mL vial, 1 count (NDC 63323-0773-11)

10 mL vial, 10 count (NDC 63323-0773-10)

10 mL vial, 1 count (NDC 55390-0045-01)

10 mL vial, 10 count (NDC 00703-4805-03)

Revised

3/15/2012

Mesna 10 mL vial, 1 count (NDC 10019-0953-01)

10 mL vial, 10 count (NDC 10019-0953-02)

Mesnex 100 mg/mL Injection,
10 mL vial, 1 count (NDC 00338-1305-01)

10 mL vial, 10 count (NDC 00338-1305-03

Mylan Institutional
1-888-258-4199

100 mg/ml; packaged in 1,000 mg/10 ml Multiple- dose vials

1-888-386-1300

25 mg/mL; 2 mL vial;
With Preservative
(NDC 63323-0123-02)

25 mg/mL; 10 mL vial;
With Preservative
(NDC 63323-0123-10)

25 mg/mL; 2 mL vial; Preservative Free
(NDC 55390-0031-10)
25 mg/mL; 4 mL vial; Preservative Free
(NDC 55390-0032-10)
25 mg/mL; 8 mL vial; Preservative Free
(NDC 55390-0033-10)
25 mg/mL; 10 mL vial; Preservative Free
(NDC 55390-0034-10) 

Methotrexate lyophilized powder for injection
1 gram vial; (NDC 55390-0143-01

25 mg/mL; 2 mL vial
With Preservative
(NDC 61703-350-38)

25 mg/mL; 40 mL vial;
Preservative Free
(NDC 61703-408-41)

Product 25 mg/mL; 2 mL vial (NDC 61703-350-38): next delivery March.

Product 25 mg/mL; 40 mL vial (NDC 61703-408-41): Hospira is working closely with the FDA to expedite releases of product.  Hospira is releasing direct customer orders.  Hospira estimates the next delivery late March.

Revised

3/15/2012

25mg/ml; 2ml vial
Preservative Free
(NDC 10139-0062-02)

25 mg/ml; 10ml vial
Preservative Free
(NDC 10139-0062-10)

25 mg/ml; 40ml vial
Preservative Free
(NDC 10139-0062-40)

Limited quantity of 2 ml vials (NDC 10139-0062-02) and 10 ml NDC 10139-0062-10) available for emergency drop ship orders.

40 ml vials (NDC 10139-0062-40) are planned to be available again in the coming weeks.

As additional product becomes available, it will continue to be allocated via drop ship orders.

Revised

3/15/2012

25mg/ml; 2ml vial
Preservative Free
(NDC 66758-0040-02)

25mg/ml; 10ml vial
Preservative Free
(NDC 66758-0040-08)

25mg/ml; 40ml vial
Preservative Free
(NDC 66758-0041-01)

Sandoz has temporarily discontinued 2ml (NDC 66758-0040-02) and 10ml (NDC 66758-0040-08) vials.

Experiencing a back order on 40ml vials.

Reverified

3/20/2012

5 mg (100s - NDC 00781-8840-01 & 00781-5748-01; 1000s - NDC 00781-8840-10), 10 mg (100s - NDC 00781-5749-01 & 00781-8841-01; 1000s - NDC 00781-1749-10), 20 mg (100s - NDC 00781-8842-01 & 00781-5753-01; 1000s - NDC 00781-1753-10)

20 mg (100s - NDC 00781-8843-01 & 00781-5754-01)

5 mg (100s - NDC 00406-1121-01; 1000s - NDC 00406-1121-10), 10 mg (100s - NDC 00406-1122-01; 1000s - NDC 00406-1122-10), 20 mg (100s - NDC 00406-1124-01; 1000s - NDC 00406-1124-10) Methylin ER, 10 mg (100s - NDC 00406-1423-01) and 20 mg (100s - NDC 00406-1451-01)

Continued recovery as a result of previously unavailable raw material

All strengths of methylphenidate IR and ER tablets will be increasingly available as supply recovery continues, with most contracted orders being met.

Reverified

3/16/2012

5 mg (100s - NDC 53014-0531-07), 10 mg (100s - NDC 53014-0530-07), and 20 mg (100s - NDC 53014-0532-07)

Metadate ER Tablets, 20 mg (100s - NDC 53014-0594-07)

Metadate CD, 10 mg (100s - NDC 53014-0579-07), 20 mg (100s - NDC 53014-0580-07), 30 mg (100s - NDC 53014-0581-07), 40 mg (100s - NDC 53014-0582-07), 50 mg (100s - NDC 53014-0583-07), and 60 mg (100s - NDC 53014-0584-07)

UCB has availability of 5 mg IR tablets, 10 mg IR tablets and 20 mg ER tablets.  UCB anticipates release of  the 20 mg IR Tablets shortly.

Revised

3/8/2012

5 mg (100s - NDC 00591-5882-01), 10 mg (100s - NDC 00591-5883-01), and 20 mg (100s - NDC 00591-5884-01)

Noven Customer Service:
866.663.2539 

Daytrana (Methylphenidate Transdermal System)

10 mg (30s - NDC 68968-5552-3) 

15 mg (30s - NDC 68968-5553-3) 

20 mg (30s - NDC 68968-5554-3) 

30 mg (30s - NDC 68968-5555-3)

Not applicable

Currently all product is available

50 mg/mL, 5 mL vial (NDC 00517-8905-10)

5 mg/mL 2 mL vials (NDC 00409-3414-01)

Manufacturing delay.

Hospira discontinued Metoclopramide Carpuject syringes in May, 2009 and ampules in February, 2010.

Please check with your wholesaler for available inventory.

5 mg/mL, 2 mL vial, 25 count (NDC 00703-4502-04)

1 mg/mL, 2 mL vial, 25 count (NDC 63323-0411-12)

1 mg/mL, 5 mL vial, 25 count (NDC 63323-0411-25)

1 mg/mL, 10 mL vial, 10 count (NDC 63323-0411-10)

5 mg/mL, 5 mL vial, 10 count (NDC 63323-0412-05)

5 mg/mL, 10 mL vial, 10 count (NDC 63323-0412-10)

5 mg/mL, 2 mL vial, 25 count (NDC 63323-0412-02)

5 mg/mL, 1 mL fill in 2 mL vial, 25 count (NDC 63323-0412-25)

1 mg/mL, 2 mL preservative-free vial, 10 count (NDC 55390-0137-02)

1 mg/mL, 5 mL preservative-free vial, 10 count (NDC 55390-0137-05)

1 mg/mL, 10 mL vial, 10 count (NDC 55390-0125-10)

5 mg/mL, 2 mL preservative-free vial, 10 count (NDC 55390-0138-02)

5 mg/mL, 1 mL preservative-free, in 2 mL vial, 10 count (NDC 55390-0138-01)

5 mg/mL, 5 mL vial, 10 count (NDC 55390-0126-05)

5 mg/mL, 10 mL vial, 10 count (NDC 55390-0126-10)

Bedford has all midazolam presentations on back order and the company cannot estimate a release date.

The 1 mg/mL 2 mL and 10 mL vials and the 5 mg/mL 2 mL (1 mL fill), 5 mL and 10 mL vials vials are pending release while the other presentations will not be manufactured until capacity permits.

Bedford Laboratories has temporarily suspended the distribution of Ben Venue Laboratories manufactured products.  Availability of products is updated on the Bedford Laboratories website

1 mg/mL, 2 mL preservative-free Luer-lock syringe (NDC 0409-2306-62)

1 mg/mL, 2 mL preservative-free vial (NDC 0409-2305-17)

1 mg/mL, 5 mL preservative-free vial (NDC 0409-2305-05)

1 mg/mL, 2 mL preservative-free iSecure syringe (NDC 0409-2306-12)

1 mg/mL, 10 mL vial (NDC 0409-2587-05)

5 mg/mL, 1 mL preservative-free vial (NDC 0409-2308-01)

5 mg/mL, 5 mL vial (NDC 0409-2596-03)

5 mg/mL, 10 mL vial (NDC 0409-2596-05)

5 mg/mL, 1 mL preservative-free Luer-Lock syringe (NDC 0409-2307-60)

5 mg/mL, 2 mL preservative-free vial (NDC 0409-2308-02)

Product 1 mg/mL, 2 mL preservative-free Luer-lock syringe (NDC 0409-2306-62): next delivery March.

Product 1 mg/mL, 2 mL preservative-free vial (NDC 0409-2305-17): next delivery March.

Product 1 mg/mL, 5 mL preservative-free vial (NDC 0409-2305-05): next delivery March.

Product 1 mg/mL, 2 mL preservative-free iSecure syringe (NDC 0409-2306-12): next delivery April.

Product 1 mg/mL, 10 mL vial (NDC 0409-2587-05): next delivery March.

Product 5 mg/mL, 1 mL preservative-free vial (NDC 0409-2308-01): next delivery March.

Product 5 mg/mL, 5 mL vial(NDC 0409-2596-03): next delivery April.

Product 5 mg/mL, 10 mL vial (NDC 0409-2596-05): next delivery March.

Product 5 mg/mL, 1 mL preservative-free Luer-Lock syringe (NDC 0409-2307-60): next delivery 2013.

Product 5 mg/mL, 2 mL preservative-free vial (NDC 0409-2308-02): next delivery April.

Hospira discontinued the following products:
1 mg/mL, 2 mL iSecure syringe (NDC 0409-2306-22)
5 mg/mL, 1 mL preservative-free iSecure syringe (NDC 0409-2307-21)

1 mg/mL, 2 mL vial, 10 count (NDC 10019-0028-02)

1 mg/mL, 2 mL dosette vial (NDC 10019-0028-03)

1 mg/mL, 5 mL vial, 10 count (NDC 10019-0028-05)

1 mg/mL, 10 mL vial, 10 count (NDC 10019-0028-10)

1 mg/mL, 2 mL vial, 25 count (NDC 10019-0028-04)

1 mg/mL, 2 mL latex free vial, 10 count (NDC 10019-0028-01)

5 mg/mL, 1 mL vial, 10 count (NDC 10019-0027-06)

5 mg/mL, 1 mL vial, 25 count (NDC 10019-0027-09)

5 mg/mL, 2 mL vial, 25 count (NDC 10019-0027-08)

5 mg/mL, 2 mL vial, 10 count (NDC 10019-0027-07)

5 mg/mL 10 mL vial, 10 count (NDC 10019-0027-10)

West-Ward is currently experiencing a backorder situation on the majority or Midazolam codes.  Limited quantities are available of the 1 mg/mL and 5 mg/mL, 2 mL vials.

West-Ward has accelerated production and will have units of all presentations available for release in the March – April 2012 timeframe.

Additional lots are also projected to be manufactured in May 2012.
Product will be made available as it is released.

Revised

3/15/2012

Revised 

3/16/2012

5 mg (NDC 16729-0115-05)
20 mg (NDC 16729-0108-11)
40 mg (NDC 16729-0116-38)

5 mg (NDC 55390-0251-01), 20 mg (NDC 55390-0252-01), 40 mg (NDC 55390-0253-01)

Hospira, Inc.
Customer Service:
1-877-946-7747

1 mg/mL, 30 mL PCA vial (NDC 0409-2029-02)

5 mg/mL; 30 mL PCA vial (NDC 0409-6028-04)

2 mg/mL; 1 mL Carpuject (NDC 0409-1762-30)

4 mg/mL; 1 mL Carpuject (NDC 0409-1258-30)

8 mg/mL; 1 mL Carpuject (NDC 0409-1260-69)

10 mg/mL; 1 mL Carpuject (NDC 0409-1261-30)

15 mg/mL; 1 mL Carpuject syringes (NDC 0409-1264-31)

50 mg/mL, 20 mL vial (NDC 0409-1134-03)

50 mg/mL, 50 mL vial (NDC 0409-1134-05)

25 mg/mL; 4 mL Add-vantage vial (NDC 0409-6177-14)

25 mg/mL, 10 mL Add-Vantage vial (NDC 0409-6179-14)

Product 8 mg/mL; 1 mL Carpuject (NDC 0409-1260-69): next delivery April.

Product 10 mg/mL; 1 mL Carpuject (NDC 0409-1261-30): next delivery March.

Product 15 mg/mL; 1 mL Carpuject syringes (NDC 0409-1264-31):  next delivery August (prioritizing other more critical products first).

Hospira has the following presentations of morphine injection available:
Product 50 mg/mL, 20 mL vial (NDC 0409-1134-03)
Product 50 mg/mL, 50 mL vial (NDC 0409-1134-05)
Product 25 mg/mL; 4 mL Add-vantage vial (NDC 0409-6177-14)
Product 25 mg/mL, 10 mL Add-Vantage vial (NDC 0409-6179-14)
 
Please check with your wholesaler for available inventory.

Revised

3/15/2012

Morphine Injection
1 mg/mL, 10 mL Luer-lock syringes (NDC 00548-3391-00

Morphine injection

1 mL vial, 5 mg/mL
(NDC 0641-6073-25)

1 mL vial, 8 mg/mL
(NDC 0641-6075-25)

1 mL vial, 10 mg/mL)
(NDC 0641-6070-25)

10mL vial, 10 mg/mL
(NDC 0641-6068-01)
1 mL vial, 15 mg/mL
(NDC 0641-6071-25)

20 mL vial, 15 mg/mL
(NDC 0641-6072-01)

West-Ward has limited availability of the 15 mg/mL, 1 mL vial and 10 mg/mL in both 1 mL and 10 mL vials.  All other presentations are on backorder.

West-Ward has accelerated production on all morphine codes and is projecting to have multiple lots available by the end of March with additional units released in April 2012.

Additional lots are also scheduled to be manufactured with an estimated availability in the May - June 2012 timeframe.

Product will be made available as it is released.

Revised

3/16/2012

0.5 mg/mL 2 mL ampule, 10 count (NDC 63323-0291-80)

0.5 mg/mL 10 mL vial, 5 count (NDC 63323-0291-10)

1 mg/mL 2 mL ampule, 10 count (NDC 63323-0292-80)

1 mg/mL, 10 mL vial (NDC 63323-0292-10)

0.5 mg/mL; 10 mL vial (NDC 0409-3814-12) 1 mg/mL; 10 mL vial (NDC 0409-3815-12)

25 mg/mL; 1 mL vial (NDC 0409-1135-02)

Product 1 mg/mL; 10 mL vial (NDC 0409-3815-12): next delivery March.

Product 25 mg/mL; 1 mL vial (NDC 0409-1135-02): next delivery June

Morphine injection

West-Ward Pharmaceuticals
Customer Service:
1-800-631-2174 (Formerly a Baxter Product)

Infumorph
20 mL ampul, 10 mg/mL (NDC 60977-114-01)

20 mL ampul, 25 mg/mL (NDC 60977-115-01)

Duramorph 10 mL ampul, 1 mg/mL) (NDC 60977-017-01)

10mL ampul, 0.5 mg/mL (NDC 60977-016-02)

West-Ward is currently experiencing a backorder situation on the Infumorph 25 mg/mL, 20 mL ampul and Duramorph 1 mg/mL, 10 mL ampul.  Limited quantities of the other Infumorph and Duramorph codes are available.

West-Ward has accelerated production on all preservative-free morphine codes and will have the following products available.

Lots of both Infumorph codes are scheduled for production and will be available for release by the middle of May 2012.

Several lots of Duramorph are scheduled for manufacturing at the end of March.  Additional lots are projected to be manufactured and available in April 2012
Product will be made available as it is released.

MVI-12 Adult; 10 mL vial (NDC 61703-423-81)
MVI-12 Adult; 2x50 mL PBP(NDC 61703-423-83)
MVI Adult; 10 mL vial (NDC 61703-422-81) MVI Adult; 2x5 mL (NDC 61703-422-82) MVI Adult 2x50 mL PBP (NDC 61703-422-83)
MVI Pediatric; 5 mL vial (NDC 61703-421-53)

Baxter (Infuvite adult and pediatric IV solution)
Customer Service:
1-888-229-0001

INFUVITE Pediatric, Multiple Vitamins for Injection. Single Dose package. (NDC 54643-5646-1)

INFUVITE Adult, Multiple Vitamins for Injection. Single dose package. (NDC 54643-5649-1)

INFUVITE Adult, Multiple Vitamins for Injection. Bulk package. (NDC 54643-5649-2)

INFUVITE Pediatric, Multiple Vitamins for Injection. Bulk package. (NDC 54643-5647-0)

Baxter is the distributor of INFUVITE Multi Vitamins. Baxter has these multi-vitamin products on allocation and is working with the manufacturer to maximize the availability of INFUVITE Multi Vitamins.

For detailed clinical recommendations to use during this shortage, please see information posted by the American Society of Parenteral and Enteral Nutrition  

Lundbeck has transferred production of Mustargen to a new manufacturing site and is in the process of securing supplies to reintroduce the product

Lundbeck expects Mustargen to be available again during second quarter 2012. Updates will be provided as they become available.

NDC and Product Description:
10 mg/mL; 1 mL amp NDC 0409-1463-01

10 mg/mL; 10 mL vial NDC 0409-1464-01

20 mg/mL; 1 mL amp NDC 0409-1465-01

10 mg/mL; 10 mL vial NDC 0409-1467-01

Naloxone 0.4 mg/mL Injection (NDC 00409-1215-01

Product Naloxone 0.4 mg/mL Injection (NDC 00409-1215-01): next delivery April.

Please check with your wholesaler for available inventory.

50 mg oral tablets
100 count (NDC 00406-1170-01)
30 count (NDC 00406-1170-03)

Revised

3/16/2012

50 mg oral tablets, 100 count (NDC 00185-0039-01)

If you have additional questions about the status of Neupro, or about UCB’s Patient Access program for Neupro, please contact UCB Medical Information at 1-866-822-0068 (option 9).

2 mL vials, package of 25 (NDC 63323-0373-02)

Limited quantities of the 20 mL multiple dose vials (NDC 63323-0374-20) are available.

Bedford
Customer Service:
1-800-562-4797

20 mL vial (NDC 55390-0121-01)

2 mL vials, packages of 10 (NDC 55390-0121-10) - discontinued
2 mL Novaplus vials, packages of 10 (NDC 55390-0307-10) - discontinued 20 mL Novaplus vials, packages of 1 (NDC 55390-0307-01) - discontinued

Bedford has ondansetron 2 mg/mL 20 mL vials on back order and the company cannot estimate a release date. Bedford Laboratories has multiple products affected by this temporary suspension of manufacturing. Bedford will have the affected, as well as the available products, listed on their website and are updating this information as it changes. The company voluntarily suspended all manufacturing and distribution in mid-November, 2011 on a temporary basis for maintenance and requalification of equipment. Product will become available in stages as production resumes.

Bedford discontinued the following products:
2 mL vials, packages of 10 (NDC 55390-0121-10)
2 mL Novaplus vials, packages of 10 (NDC 55390-0307-10)
20 mL Novaplus vials, packages of 1 (NDC 55390-0307-01)

2 mL vials, package of 5 (NDC 60505-0744-01)

20 mL multiple dose vial (NDC 60505-0744-06)

Revised

3/2/2012

2 mL ampules (NDC 62756-0181-01)

20 mL vials (NDC 62756-0182-01)

2 mL vials, packages of 5 (NDC 46860-0087-06)

2 mg/mL; 2 mL vials (NDC 0409-4755-03)

2 mg/mL; 20 mL vials (NDC 0409-4759-01)

0.64 mg/mL; 50 mL bag (32 mg/50 mL) (NDC 0409-4760-24

Product 2 mg/mL; 2 mL vial (NDC 0409-4755-03): next delivery March.

Product 2 mg/mL; 20 mL vial (NDC 0409-4759-01): next delivery March.

Product 0.64 mg/mL; 50 mL bag (32 mg/50 mL) (NDC 0409-4760-24): next delivery 2012.

Product 2 mg/mL; 2 mL iSecure syringe (NDC 0409-1120-12): next delivery March.

Please check with your wholesaler for available inventory.

Reverified

3/2/2012

Customer Service:
1-800-631-2174
(Formerly a Baxter Product)

2 mg/mL, 2 mL vial (NDC 0641-6078-25)

2 mg/mL, 20 mL

Vial (0641-6079-01)

West-Ward is currently experiencing a backorder situation on both the 2 mL and 20 mL vials.

West-Ward has accelerated production and is projecting to have additional units available. 

Lots are scheduled for release in March and April 2012.
Product will be made available as it is released.

Revised

3/15/2012

20 mL vials (NDC 00703-7226-01)

2 mL vials, packages of 5 (NDC 00703-7221-02) - discontinued

Zofran injection, 2 mg/mL,
2 mL vials, packages of 5
(NDC 00173-00442-02)

20 mL vial
(NDC 00173-0442-00)

20 mL vial (NDC 00173-0442-00)

GlaxoSmithKline has discontinued Zofran 2 mL vials

2 mL vials, package of 5 (NDC 64679-0726-01)

20 mL vials, package of 1 (NDC 64679-0727-01))

Revised

3/9/2012

Pfizer
1-800-533-4535

Ondansetron
4 mg/2mL x 25 count
(preservative fee, latex free) NDC 0069-1340-16

40mg/20mL x 1 MDV NDC 0069-1340-02

2 mL vials, package of 25 (NDC 0069-1340-16)
20 mL vials, package of 1 (NDC 0069-1340-02)

32 mg/50 mL (NDC 36000-0014-06)

32 mg/50 mL (NDC 25021-0776-50) - discontinued

32 mg/50 mL (NDC 00703-7239-39)

0.64 mg/mL; 50 mL bag
(32 mg/50 mL)
(NDC 0409-4760-24)

Reverified

3/2/2012

32 mg/50 mL
(NDC 00143-9771-06)

32 mg/50 mL (NDC 00338-1762-41)

150 mcg/mL, Eisai
2 mL vial (NDC 62856-0603-01)

30 mg/mL, 2 mL vial, 10 count (NDC 17478-0538-02)

Revised

3/16/2012

Bedford
2 mL vial, 10 count (NDC 55390-0059-10)

Sagent:
1-866-625-1618
 

30 mg/mL, 2 mL vial, 10 count (NDC 25021-0651-02)

Available

Watson:
Orphenadrine citrate injection

30 mg/mL, 2 mL vial, 10 count (NDC 00591-3222-47)

5mg tablets, 100 count (NDC 00054-0283-25)

10mg tablets, 100 count (NDC 00054-0284-25)

Endo Pharmaceuticals Inc.
1-800-462-3636

Opana (oxymorphone hydrochloride):

10mg tablet, 100 count bottle (NDC 63481-0613-70)

5mg tablet, 100 count bottle (NDC 63481-0612-70)

Oxymorphone Hydrochloride:

10mg tablet, 100 count bottle (NDC 60951-0795-70)

5mg tablet, 100 count bottle (NDC 60951-0794-70)

10 mL MDV (10 USP units/mL)
(NDC 63323-012-10)

1 mL SDV (Plastic Vial) (10 USP units/mL)
(NDC 63323-012-01)

30 mL MDV (10 USP units/mL)
(NDC 63323-012-30)

10 mL vial on back-order with an estimated release date of early to mid-February 2012.

1 mL vial available with an estimated release date of mid-January 2012

30 mL vial available. Estimated release date TBD.

1 mL vial (10 USP units/mL)
(NDC 42023-116-25)

10 mL vial (10 USP units/mL)
(NDC 42023-116-01)

10 mL vial (10 USP units/mL)
(NDC 42023-116-02)

1 mL SDV is currently on short-term back-order. Company has increased production with an estimated release date of early February 2012.

10 mL vial in 1 and 25s: Available in adequate stock.

Please see product status memo: Short Term Backorder Status Letter (PDF - 95KB)

1mL vial (10 USP units/mL) (NDC10019-291-02)

10 mL vial (10 USP units/mL)
(NDC 10019-291-04

30 mg/5 mL vial (NDC 66578-0043-01) 100 mg/16.7 mL vial (NDC 66578-0043-02) 300 mg/50 mL vial (NDC 66578-0043-03)

Reverified

3/16/2012

30 mg/5 mL vial (NDC 63323-0763-05)
100 mg/16.7 mL vial (NDC 63323-0763-16)
300 mg/50 mL vial (NDC 63323-0763-50)

Reverified

3/12/2012

Hospira Inc. Customer Service:
1-877-946-7747

300 mg/50 mL vial (NDC 0409-0342-50)

30 mg/5 mL vial (NDC 0409-0342-09)

100 mg/16.7 mL vial (NDC 0409-0342-22)

Product 30 mg/5 mL vial (NDC 0409-0342-09): ample levels of inventory to support market demand.
 
Product 300 mg/50 mL vial (NDC 0409-0342-50):  ample levels of inventory to support market demand.
 
Product 100 mg/16.7 mL vial (NDC 0409-0342-22): next delivery April.

Please check with your wholesaler for available inventory.

Revised

3/15/2012

30 mg/5 mL vial (NDC 55390-0114-05)
100 mg/16.7 mL vial (NDC 55390-0114-20)
300 mg/50 mL vial (NDC 55390-0114-50)

30 mg/5 mL vial (NDC 00703-4764-01)
100 mg/16.7 mL vial (NDC 00703-4766-01)
150 mg/25 mL vial (NDC 00703-4767-01)
300 mg/50 mL vial (NDC 00703-4768-01)

30mg/5mL
NDC 25021-213-05

100mg/16.7mL
NDC 25021-213-17

300mg/50mL
NDC 25021-213-50

1 mg/mL; 10 mL vial
(NDC 0409-4646-01)

Phentolamine mesylate for injection, 5 mg lyophilized vial (NDC 55390-0113-01)

1 mg/0.5 mL; 0.5 mL amp
(NDC 0409-9157-01)

10 mg/mL; 1 mL amp
(NDC 0409-9158-01)

Product 1 mg/0.5 mL; 0.5 mL amp (NDC 0409-9157-01): next delivery March.

Product 10 mg/mL; 1 mL amp (NDC 0409-9158-01): next delivery March.

Please check with your wholesaler for available inventory.

Vitamin K injection, contains polysorbate 80 and propylene glycol

1 mg/0.5 mL, SAF-T-JET prefilled syringe (NDC 00548-1240-00)

1 mg/0.5 mL, MINIJET prefilled syringe (NDC 00548-1140-00)

Hospira Inc.
(1-877-946-7747)

3 mMol/mL; 15 mL vial

(NDC 0409-7295-01)

Product 3 mMol/mL; 15 mL vial (NDC 0409-7295-01):  next delivery June.

Reverified

3/2/2012

3 mMol/mL, 15 mL vial (NDC 00517-2315-25)

3 mMol/mL, 50 mL vial (NDC 00517-2350-25)

Manufacturing delays    

100 mg/mL; 10 mL vial

(NDC 0409-1902-01)

500 mg/mL; 2 mL vial

(NDC 0409-1903-01)

Product 500 mg/mL; 2 mL vial (NDC 0409-1903-01):  next delivery in May.

Product 100 mg/mL; 10 mL vial (NDC 0409-1902-01):  ample levels of inventory to support market demand.

Please check with your wholesaler for available inventory.

5 mg/mL

2 mL vial, 10 count (NDC 55390-0077-10)

10 mL vial (NDC 55390-0077-01)

25 mg/mL 1 mL
Carpuject
(NDC 0409-2312-31)

Reverified

3/2/2012

25 mg/mL; 1 mL vial (NDC 00703-2191-04)

50 mg/mL; 1 mL vial (NDC 00703-2201-04

25 mg/mL;1 mL dosette ampule (NDC 00641-1495-35)
25 mg/mL; 1 mL vial (NDC 00641-0928-25)
25 mg/mL; 1 mL vial (NDC 00641-6084-25)
50 mg/mL; 1 mL vial (NDC 00641-0929-25)
50 mg/mL; 1 mL Novaplus vial (NDC 00641-0956-25)

25 mg/mL; 1 mL ampule (NDC 60977-0001-01)
50 mg/mL; 1 mL dosette vial (NDC 60977-0002-04)

West-Ward is currently experiencing a backorder situation on Promethazine 25 mg/mL,1 mL vial, 50 mg/mL, 1 mL ampul and Phenergan 25 mg/mL, 1 mL vial.  All other codes are available in limited quantities.

West-Ward has accelerated production and will have units of all presentations available for release in the March – April 2012 timeframe.

Product will be made available as it is released

Revised

3/19/2012

40 mg vial, package of 10 (NDC 00008-0923-55)

40 mg vial, package of 25 (NDC 00008-0923-60)

40 mg Novaplus vial, package of 10 (NDC 00008-0941-04)

Pfizer has limited supply of 40mg in 25 (00008-0923-60) until June 2012.

40 mcg/mL, 10 mL vial (NDC 00517-6610-25)

2 mEq/mL, 100 mL vial (NDC 63323-0032-61)

Revised

3/12/2012

American Regent, Inc./Luitpold
1-800-645-1706

2 mEq/mL, 20 mL vial (NDC 00517-2096-25)

2 mEq/mL, 100 mL vial (NDC 00517-2500-25)

4 mEq/mL, 50 mL vial (NDC 00517-5023-25)

American Regent anticipates to have the 50 mL vial available end of March 2012.

The 100 mL vial has been discontinued.

Sodium Bicarbonate Injection USP, 8.4%, 50 mL Prefilled Syringe NDC: 0548-3352-

5 mL vial (NDC 63323-0026-05

4%; 5 mL vial (NDC 0409-6609-02)

0.5 mEq/mL; 10 mL Abboject (NDC 0409-5534-34)

0.9 mEq/mL; 50 mL Abboject (NDC 0409-4916-34)

1 mEq/mL; 50 mL vial (NDC 0409-6625-02)

1 mEq/mL; 50 mL Abboject (NDC 0409-6637-34)

1 mEq/mL; 10 mL Abboject (NDC 0409-4900-34

Product 4%; 5 mL vial (NDC 0409-6609-02):  next delivery April.

Product 0.5 mEq/mL; 10 mL Abboject (NDC 0409-5534-34):  next delivery April.

Product 0.9 mEq/mL; 50 mL Abboject (NDC 0409-4916-34):  next delivery March.

Product 1 mEq/mL; 50 mL vial (NDC 0409-6625-02):  next delivery April Product 1 mEq/mL; 50 mL Abboject (NDC 0409-6637-34):  next delivery March.

Product 1 mEq/mL; 10 mL Abboject (NDC 0409-4900-34):  next delivery April. Please check with your wholesaler for available inventory

30 mL vials (NDC 63323-0087-30)
100 mL vials (NDC 63323-0088-61)
200 mL vials (NDC 63323-0088-63)

Reverified

3/12/2012

30 mL vials (NDC 00517-2930-25), 100 mL vials (NDC 00517-2900-25)

Reverified

3/19/2012

4 mEq/mL; 250 mL bottle (NDC 0409-1130-02)
4 mEq/mL; 100 mL bottle (NDC 0409-1141-02)

Product 4 mEq/mL; 250 mL bottle (NDC 0409-1130-02):  expected availability is TBD.

Product 4 mEq/mL; 100 mL bottle (NDC 0409-1141-02):  expected availability is TBD.

3 mmol/mL, 15 mL vial (NDC 00409-7391-72)

Product 3 mmol/mL; 15 mL vial (NDC 0409-7391-72): ample supply available.

5 mmol/mL, 5 mL vial (NDC 00517-3405-25), 5 mmol/mL, 15 mL vial (NDC 00517-3415-25), 5 mmol/mL, 50 mL vial (NDC 00517-3450-25)

Sufenta 50 mcg/mL

1 mL ampule (NDC 17478-0050-01)

2 mL ampule (NDC 17478-0050-02)

2 mL  ampoule (NDC 17478-0050-02)-Releasing next week (week of March 19th)

5 mL ampoule (NDC 17478-0050-05)-Targeted release in May

Hospira, Inc.
Customer Service:
1-877-946-7747

Sufentanil 50 mcg/mL

1 mL ampule (NDC 0409-3380-31)

1 mL vial (NDC 0409-3382-21)

2 mL ampule (NDC 0409-3380-32)

2 mL Novaplus ampule (NDC 0409-3380-50)

2 mL vial (NDC 0409-3382-22)

5 mL ampule (NDC 0409-3380-35)

5 mL vial (NDC 0409-3382-25)

Product 50 mcg/mL; 2 mL vial (NDC 0409-3382-22): next delivery August.

Product 50 mcg/mL; 5 mL vial (NDC 0409-3382-25): next delivery August.

Product 50 mcg/mL; 1 mL ampule (NDC 0409-3380-31): next delivery September.

Product 50 mcg/mL; 2 mL ampules (NDC 0409-3380-32). next delivery September

Product 50 mcg/mL; 5 mL ampule (NDC 0409-3380-35): next delivery July.

Please check with your wholesaler for all available inventory.

Revised

3/15/2012

Sufentanil 50 mcg/mL
1 mL ampule (NDC 10019-0050-43)

2 mL ampule (NDC 10019-0050-21)

5 mL ampule (NDC 10019-0050-06)

West-Ward is currently experiencing a backorder situation on all presentations due to an increase in market demand. 

Multiple lots of the 5 mL ampul are anticipated to be released and available in the April - May 2012 timeframe.

No update is available at this time on the availability of the 1 mL and 2 mL ampuls,
Product will be made available as it is released.

Revised

3/19/2012

Teva Pharmaceuticals
1-800-545-8800

80 mg/trimethoprim 16 mg/mL injection
5 mL vial (NDC 00703-9503-03)
10 mL vial (NDC 00703-9514-03)
30 mL vial (NDC 00703-9526-01)

NDC 00469-3575-50
PDS 750 mg

NDC 00469-3525-30
PDS 250 mg

Astellas has no estimated date of availability.

See the Dear Health Care Provider Letter (PDF - 142KB)

250 mg, 100 count (NDC 00172-2416-60)

250 mg, 100 count unit dose (NDC 00172-2416-10)

250 mg, 1000 count (NDC 00172-2416-80)

500 mg, 100 count (NDC 00172-2407-60)

500 mg, 100 count unit dose (00172-2407-10)

500 mg, 1000 count (NDC 00172-2407-80)

250 mg, 100 count (NDC 00591-2234-01)

250 mg, 1000 count (NDC 00591-2234-10)

500 mg, 100 count (NDC 00591-2235-01)

500 mg, 1000 count (NDC 00591-2235-10)

15 mg/mL vial (NDC 55390-0030-10)

250 mg, 100 count (NDC 00093-0154-01)

Revised

3/2/2012

250 mg, 30 count (NDC 60505-0027-02)

250 mg, 60 count (NDC 60505-0027-04)

250 mg, 500 count (NDC 60505-0027-07)

Teva Pharmaceuticals
1-800-545-8800

40 mg/mL, 2 mL vial (NDC 00703-9402-04)

40 mg/mL, 30 mL vial (NDC 00703-9416-01)

Reverified

3/15/2012

Pfizer Injectables
1-800-533-4535

40 mg/mL, 2 mL vial (NDC 00069-0088-02)

40 mg/mL, 30 mL vial (NDC 00069-0091-03)

APP
1-888-386-1300

10 mg/ml; 2ml vial (NDC 63323-0305-02)
40 mg/mL, 2 mL vial (NDC 63323-0306-02)
40 mg/mL, 30 mL vial (NDC 63323-0306-30)
 
40 mg/mL, 50 mL vial (NDC 63323-0307-51)

40 mg/mL, 2 mL  Novaplus vial (NDC 63323-0306-55)
 
40 mg/mL, 30 mL Novaplus vial (NDC 63323-0306-56)

Tobramycin Lyophilized Powder for Injection
1.2 gram 50 mL vial, preservative-free, 6 count (NDC 63323-0303-51)
 1.2 gram 50 mL Novaplus vial, preservative-free, 6 count (NDC 63323-0303-55)

The 40 mg/mL 2 mL vials are available – check wholesalers for inventory.

APP has tobramycin solution for injection 10 mg/mL 2 mL vials on intermittent back order. Product may be available at wholesalers.

The 40 mg/mL 50 mL vials are available.  Please check wholesaler inventory.

Revised

3/12/2012

10 mg/mL; 2 mL vial
(NDC 0409-3577-01)

40 mg/mL; 2 mL vial
(NDC 0409-3578-01)

40 mg/mL; 50 mL vial
(NDC 0409-3590-02)

Product 10 mg/mL; 2 mL vial (NDC 0409-3577-01): next delivery June.
Product 40 mg/mL; 2 mL vial (NDC 0409-3578-01): next delivery April.
Product 40 mg/mL; 50 mL vial (NDC 0409-3590-02): next delivery April

.
Please check with your wholesaler for available inventory.

20 units/mL; 0.5 mL multi-dose vial, 25 count (NDC 00517-0510-25)

20 units/ml; 1 mL multi-dose vial, 25 count (NDC 00517-1020-25)

20 units/ml; 10 mL multi-dose vial, 25 count (NDC 00517-0410-10)

American Regent has 0.5 mL multi-dose vial available.

1 mL multi-dose vial on back order and will be available end of April 2012.

10 mL multi-dose vial on back order and will be available end of April 2012.

Vecuronium Bromide for Injection 10 mg 10 vials NDC 41616-0931-44

Vecuronium Bromide for Injection 20 mg 10 vials NDC 41616-0932-44

Teva Pharmaceuticals
1-800-545-8800

10 mg vials, package of 10 (NDC 00703-2914-03)
20 mg vials, package of 10 (NDC 00703-2925-03)

10 mg vial (NDC 0409-1632-01)

20 mg vial (NDC 0409-1634-01)

Manufacturing delay

10mg/vial
NDC 25021-657-10

20mg/vial
NDC 25021-658-20

1 mg/mL; 10 mL vial (NDC 63323-0278-10)

100 gram, 3 count (NDC 63481-0684-03)
100 gram, 5 count (NDC 63481-0684-05)

1 mg/mL, 10 mL vial
(NDC 00517-6110-25)

5 mg/mL, 5 mL vial
(NDC 00517-8105-25)

100 gram, 3 count
(NDC 63481-0684-03)

100 gram, 5 count
(NDC 63481-0684-05)

1 mg/mL, 10 mL vial
(NDC 0409-4090-01)

Please check with your wholesaler for all available inventory.